Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hammi

- PMLiVE

UK, Germany back routine use of J&J’s Tremfya

The IL-23 inhibitor is currently being assessed in other EU countries

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

- PMLiVE

Janssen named ‘Pharma Company of the Year’ at business intelligence awards

Adelphi Research takes home ‘Agency of the year’ trophy

- PMLiVE

FDA clears first-line use for J&J’s Darzalex

Front-line approval a milestone for blockbuster-tipped myeloma drug

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

J&J pays $140m upfront for cancer-busting virus firm BeneVir

The total value of the deal could go above $1bn if the biotech’s candidates perform well

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

- PMLiVE

J&J takes option on Theravance’s JAK drug in $1bn deal

TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients

Merck to pilot digital behavioural change programme

Will work with US digital therapeutics firm Blue Mesa Health in diabetes

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links